Release Date: 30/03/15 09:18 Summary: ANI First Supplementary Target's Statement & Presentation Price Sensitive: Yes Download Document 723.73KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%